Researchers report that the weight loss drugs semaglutide and tirzepatide can reduce the risk of hospitalization and death by 40% in people with a common type of heart failure. Experts say this large ...

An international clinical trial has found that an oral form of semaglutide, a widely used diabetes drug, reduced the risk of serious heart failure events in people with type 2 diabetes who already had ...

Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity and type 2 ...

Targeted therapies for transthyretin amyloid cardiomyopathy (ATTR-CM) were associated with significant reductions in all-cause mortality and cardiovascular hospitalizations compared with untreated ...

While proven to help, primary care clinicians have been slow to use the drugs once considered only for patients with diabetes.

Both semaglutide and tirzepatide were shown to “significantly reduce” the risk of hospitalization and all-cause mortality for heart failure patients, according to a study published Aug. 31 in JAMA.

Treatment of heart failure patients with these therapies led to fewer hospitalizations and lower calorie intake, which together translated into decreased greenhouse gas emissions, less medical waste, ...

Beta-blocker therapy significantly reduced a composite endpoint of all-cause mortality, new myocardial infarction (MI) and heart failure (HF) compared with no beta-blocker therapy in the subgroup of ...

MINNEAPOLIS — A reduced risk for death may balance out concerns about hyperkalemia when treating heart failure with renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists ...

Most people think of heart disease, kidney disease and diabetes as separate problems. In reality, they are tightly ...

Researchers report that the weight loss drugs semaglutide and tirzepatide can reduce the risk of hospitalization and death by 40% in people with a common type of heart failure. Experts say this large ...